Droxidopa
Back to searchMolecule Structure
Scientific Name
Droxidopa
Description of the Drug
Droxidopa is a medication used to treat symptomatic neurogenic orthostatic hypotension (nOH) caused by dopamine beta-hydroxylase deficiency, non-diabetic autonomic neuropathy and primary autonomic failure caused by conditions such as Parkinson’s disease.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06262
http://www.drugbank.ca/drugs/DB06262
Brand Name(s)
Northera
Company Owner(s)
Teva Pharmaceuticals Usa Inc, Alkem Laboratories Ltd, Ajanta Pharma Ltd, Msn Pharmaceuticals Inc, Tris Pharma Inc, Lupin Pharmaceuticals Inc, Celltrion Inc, Sun Pharmaceutical Industries Ltd, Zydus Pharmaceuticals Usa Inc, Upsher Smith Laboratories Llc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Adrenergic receptor | PROTEIN FAMILY | AGONIST | CHEMBL2331074 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL134299 | |
DrugBank | DB06262 | |
PubChem: Thomson Pharma | 14748940 | 15220262 |
PubChem | 6989215 | 92974 |
Nikkaji | J22.085J | |
BindingDB | 50103611 | |
DrugCentral | 971 | |
Metabolights | MTBLC31524 | |
Brenda | 45621 | 45502 |
ChemicalBook | CB1699324 | CB3208010 |
Guide to Pharmacology | 7391 | |
rxnorm | NORTHERA | DROXIDOPA |
PubChem: Drugs of the Future | 12013905 | |
ChEBI | 31524 | |
ZINC | ZINC000001482049 |